{"date": "2018-01-17_21:25:09", "url": "http://www.eurekalert.org/pub_releases/2017-02/sri-tco022117.php", "year": "Tue, 21 Feb 2017 05:00:00 GMT", "text": ["experimental", "biology", "2017april", "22", "26", "2017chicago", "il2018", "aaas", "annual", "meeting", "february", "15", "19", "2018austin", "tximage", "tsri", "professor", "hugh", "rosen", "view", "february", "21", "2017", "results", "new", "phase", "3", "study", "conducted", "celgene", "corporation", "demonstrate", "ozanimod", "drug", "candidate", "originally", "discovered", "optimized", "scripps", "research", "institute", "tsri", "reduce", "frequency", "multiple", "sclerosis", "multiple", "sclerosis", "form", "disease", "patients", "experience", "periodic", "worsening", "symptoms", "sensory", "motor", "loss", "function", "leads", "increased", "disability", "patients", "need", "cane", "wheelchair", "signature", "disease", "appearance", "lesions", "brain", "linked", "inflammation", "show", "mri", "detection", "active", "periods", "multiple", "sclerosis", "discovered", "tsri", "professors", "hugh", "rosen", "ed", "roberts", "laboratories", "acts", "sphingosine", "1", "s1pr1", "receptor", "agonist", "modulating", "s1pr1", "signaling", "blocking", "sources", "inflammation", "rosen", "roberts", "went", "receptos", "clinical", "stage", "biopharmaceutical", "company", "took", "ozanimod", "phase", "1", "2", "3", "clinical", "trials", "acquired", "celgene", "ozanimod", "first", "new", "chemical", "entity", "discovered", "starting", "point", "nih", "common", "fund", "molecular", "libraries", "initiative", "reach", "succeed", "advanced", "clinical", "reported", "celgene", "results", "randomized", "phase", "3", "sunbeam", "study", "among", "participants", "show", "ozanimod", "met", "primary", "endpoint", "reducing", "annualized", "relapse", "rate", "arr", "relapsing", "multiple", "sclerosis", "compared", "alternate", "drug", "treatment", "called", "weekly", "interferon", "ifn", "doses", "1", "mg", "mg", "ozanimod", "demonstrated", "statistically", "significant", "clinically", "meaningful", "improvements", "compared", "primary", "endpoint", "arr", "measured", "secondary", "endpoints", "number", "lesions", "number", "new", "enlarging", "t2", "mri", "lesions", "year", "treatment", "exciting", "rewarding", "see", "results", "new", "phase", "3", "trial", "confirm", "safety", "profile", "extension", "data", "phase", "2", "radiance", "study", "underscore", "ozanimod", "efficacy", "reducing", "burden", "ms", "symptoms", "patients", "families", "said", "rosen", "look", "forward", "seeing", "full", "study", "results", "well", "results", "phase", "3", "study", "evaluating", "ozanimod", "patients", "ulcerative", "colitis", "scientists", "involved", "trial", "plan", "present", "full", "phase", "3", "trial", "results", "upcoming", "international", "scientific", "meeting"], "title": "TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis | EurekAlert! Science News", "source": "Scripps Research Institute"}